Last edition
News about
Emcure Receives CDSCO Nod to Expand Poviztra's Use for MASH Indication
Emcure has received CDSCO approval to expand Poviztra's use for non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), addressing a major unmet need in progressive liver disease treatment.
EMA Accepts Bexsero Label Update for Meningitis B Booster
The European Medicines Agency (EMA) has accepted a label update for Bexsero that could enable a single booster dose to protect individuals aged 10 years and older previously vaccinated against Meningitis B.
The initiative aims to equip pharmaceutical companies, biotech firms and research institutions with AI-driven molecular analysis tools to accelerate drug discovery and advance computational biology research.
Dr. Jitendra Singh Launches India's First Engineering Biology Course
India launches its first Engineering Biology course as Dr. Jitendra Singh unveils a 2035 roadmap to advance Artificial Intelligence (AI)-driven biotechnology and bio-manufacturing.
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Trial of AT-587 for Hepatitis E Treatment
Atea Pharmaceuticals has initiated a first-in-human Phase 1 clinical trial evaluating AT-587, an investigational oral antiviral candidate for hepatitis E virus (HEV) infection. The study will assess the drug's safety and pharmacokinetics, supporting the development of a potential new treatment for chronic HEV, particularly in immunocompromised patients.
Ascletis Selects Oral ASC30-ASC48 Fixed-Dose Combination for Clinical Development in Obesity
Ascletis Pharma has selected its ASC30-ASC48 fixed-dose combination for clinical development as a once-daily oral therapy for obesity. The dual-target GLP-1R/GIPR candidate demonstrated encouraging preclinical efficacy, with an IND submission to the US FDA planned for Q4 2026.
Roche's Gazyva Receives US FDA Priority Review for Membranous Nephropathy
The US Food and Drug Administration (FDA) has granted Priority Review to Roche's Gazyva for primary membranous nephropathy, supported by phase 3 MAJESTY trial results showing superior complete remission versus tacrolimus.
The collaboration between Insilico Medicine and Bora Pharmaceuticals is valued at over USD 2.5 billion if fully implemented and aims to accelerate the discovery, development and commercialisation of next-generation therapies while expanding AI adoption across the pharmaceutical value chain.
India-UK FTA to Boost Pharma Exports Beyond USD 981 Million in FY2026-27: Pharmexcil
India-UK FTA is expected to boost India's pharmaceutical exports to the UK beyond USD 981 million in FY2026-27, building on strong export growth, according to Pharmexcil.
Dr. Jitendra Singh Unveils Phase 3 of Biomedical Research Career Program
Dr. Jitendra Singh launched phase 3 of the Biomedical Research Career Programme (BRCP), backed by DBT and Wellcome Trust, to strengthen India's biomedical workforce and support a USD 300 billion bioeconomy by 2030.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy